Imaging & Analysis

The Imaging & Analysis (I&A) division develops and manufactures microscopes, scientific cameras, analytical instruments and bespoke software, with manufacturing bases in the UK (High Wycombe and Belfast), Europe (Aix-en-Provence, Ulm and Zurich) and the USA (Santa Barbara).

Orders

£317.3m

(2025: £318.6m)

Revenue

£314.7m

(2025: £330.5m)

Key highlights

Imaging & Analysis	2026	2025[1]	growth	OCC growth[2]
Order intake	**£317.3m**	£318.6m	(0.4%)	+1.3%
Revenue	**£314.7m**	£330.5m	(4.8%)	(3.0%)
Adjusted operating profit[3]	**£70.9m**	£73.2m	(3.1%)	+2.3%
Adjusted operating profit margin[3]	**22.5%**	22.1%	40bps	
OCC adjusted[3] operating margin	**23.3%**	22.1%		+120bps
Statutory operating profit	**£59.0m**	£37.8m		
Statutory operating margin	**18.7%**	11.4%		

1 FY25 restated to classify NanoScience as a discontinued operation.
2 For definition refer to note above.
3 Details of adjusting items can be found in Note 2 to the financial statements.

The I&A division brings together the Group's extensive capabilities in imaging and analysis, where we offer highly sophisticated, but relatively small-scale scientific instruments, paired with bespoke software, to a wide range of customers from academic research institutions to commercial R&D teams and volume manufacturers. The division generates strong margins and runs on a shorter order cycle than our Advanced Technologies division, where we typically sell larger scale capital equipment with longer lead times and structurally lower, albeit growing, margins.

Chief Executive Officer's review continued

Imaging & Analysis market dynamics

We have a strong divisional presence in each of our three main markets: materials analysis, semiconductors and healthcare & life science. The primary drivers of each are set out in 'Positioned in structurally growing markets' above.

Divisional performance in **materials analysis** was resilient, with a strong rebound from H1 disruption into H2, to end the year with orders broadly flat, down 0.5% CC and revenue down 3.4% OCC.

Demand for **semiconductor-related** applications was strong, with orders growing by 12.7% OCC, while revenue was down 0.9% OCC against a strong prior year comparator.

We are able to showcase our metrology capabilities to an increasing range of volume manufacturing customers via our compound semiconductor facility in Severn Beach, where we have installed a full range of Imaging & Analysis products in our state-of-the-art cleanroom, which is aiding conversion of prospects to orders.

Following early signs of order stabilisation over the past two reporting periods, the **healthcare & life science segment** has returned to order growth in H2.

We saw sustained order momentum from the start of the second half, ending H2 7.5% OCC up versus prior year and with a 29% uplift in system sales for BC43, our flagship confocal microscope. Healthcare & life science revenue was 0.9% OCC behind prior year.

Our increasing exposure to commercial customers has enhanced the resilience of the division, with growth in commercial R&D orders of 18% year-on-year more than offsetting a reduction in pure academic demand.

Increasing traction with commercial customers has also underpinned our strong recovery in China, where divisional orders were up 14% CC year on year following our pivot to new sources of funding.

Strategic and operational progress

As set out earlier in this review, the start of the year was disrupted by tariffs and uncertainty in US academic funding, resulting in a slower order flow and lower revenue in H1. However, the actions we have taken to restore order growth and manage costs, combined with the underlying strength of our market positions, and improving markets, enabled us to deliver a strong recovery in the second half, as anticipated.

We showcase our Imaging & Analysis metrology products at our Severn Beach facility

At the start of the year, we accelerated the progress of our 'Made in China' project, through which we now manufacture some of our detectors through a supply chain partner in China. This has helped to protect market share for these products, which are not strategically sensitive, in the context of increased appetite for locally produced products. We have also shifted production of some of our atomic force microscopes from Santa Barbara in California to Ulm in Germany, and moved some nanoindentation production from Zurich in Switzerland to our High Wycombe base. Both of these initiatives, completed in the second half of the year, have increased flexibility for customers as well as helping us achieve operational efficiencies, fulfilling the order book at pace.

Our swift actions in the face of US federal budget uncertainty, pivoting to new funding markets, primarily in commercial settings, have contributed to our resilient performance.

As detailed in 'Recovering cameras and microscopy business' above, our Belfast facility has been a further key focus area this year. Here, our OpEx programme continues to deliver increased productivity and quality and, more timely delivery to customers and significant inroads into repair backlogs. Progress on our OEM strategy is also encouraging, with a key OEM partner returning to Oxford Instruments from a competitor, an important framework order for cameras won with a large manufacturer, and discussions under way with a number of existing partners.

Chief Executive Officer's review continued

However, significant work and relationship building is required to achieve our full potential, and OEM partnerships will continue to be a primary focus area for FY27.

Continued investment in innovation is central to our growth plans fro I&A. New launches this year include:

New launches in Imaging & Analysis this year include:

- an easier-to-use extension to our atomic force microscopy range, which delivers excellent capabilities at a more attractive price point relevant for certain customer types, extending our market reach; this has been well received by customers, supporting strong early order intake and broadening our addressable market among both academic and commercial users;
- a significantly updated benchtop nuclear magnetic resonance instrument which has enabled us to regain technology leadership in the space;
- a new in operando high-speed nanoindenter suited to industrial settings rather than lab conditions, developed by our team in Zurich who joined as part of the acquisition of FemtoTools in 2024;
- a new suite of high-speed, high-resolution, visible light and UV scientific cameras created by the team that joined Oxford Instruments as part of the acquisition of First Light Imaging in 2024; and
- a refreshed core Raman microscope line with a groundbreaking new spectrometer, which together offer customers greater speed, ease-of-use and flexibility in obtaining research-grade results.

Across the year's launches, customer feedback and early order patterns reinforce our confidence in the commercial relevance of our innovation pipeline.

In August 2025 we shipped our first 'Made in China' XPlore detector to a customer in China

We were delighted to be awarded the Institute of Physics' Business Innovation of the Year award for our revolutionary Unity detector, which combines backscatter electron microscopy with X-ray to create detailed analysis of samples at a scale and pace not previously feasible.

We have also made good progress with the development of new products to be launched in FY27, including an extension to our range of scientific cameras, as set out in 'Sustained commitment to innovation and R&D' above.